Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.5%) at 16,894 as of Thursday, July 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 864 issues advancing vs. 2,123 declining with 163 unchanged. The Health Services industry currently sits down 0.7% versus the S&P 500, which is down 0.4%. Top gainers within the industry include HCA Holdings ( HCA), up 0.9%, and Baxter International ( BAX), up 0.9%. On the negative front, top decliners within the industry include Mettler-Toledo International ( MTD), down 1.1%, St Jude Medical ( STJ), down 0.9%, Intuitive Surgical ( ISRG), down 0.9%, Agilent Technologies ( A), down 0.8% and UnitedHealth Group ( UNH), down 0.8%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Opko Health ( OPK) is one of the companies pushing the Health Services industry higher today. As of noon trading, Opko Health is up $0.20 (2.3%) to $8.90 on average volume. Thus far, 1.5 million shares of Opko Health exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $8.59-$8.99 after having opened the day at $8.64 as compared to the previous trading day's close of $8.70. Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.5 billion and is part of the health care sector. Shares are up 3.1% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.